NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. (October 2022) - Yap, T.A.; Ngoi, N.; Dumbrava, E.E.; Karp, D.D.; Rodon Ahnert, J.; Fu, S.; Hong, D.S.; Naing, A.; Pant, S.; Piha-Paul, S.A.; Subbiah, V.; Tsimberidou, A.M.; et al.